Perhydrophenothiazine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻嗪类
• 英文名称: Perhydrophenothiazine
• 英文别名: 2,3,4,4a,5a,6,7,8,9,9a,10,10a-dodecahydro-1H-phenothiazine
• 化学式: C₁₂H₂₁NS
• 分子量: 211.37
• InChiKey: MGTISLRHMWCSLR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2,2'-dicyclohexanonyl sulfide 、 甲酰胺 、 甲酸 、 盐酸 以13%的产率得到
  参考文献：
  名称：

  KARAULOV E. S.; USOLTSEV A. A.; TILICHENKO M. N., XIMIYA GETEROTSIKL. SOEDIN. , 1976, HO 4 472-474

  摘要：

  DOI：

文献信息

• TERTIARY AMINE COMPOUND OR IMINE COMPOUND-POLYMER CONJUGATE AND PRODUCTION METHOD THEREFOR
  申请人：Seikagaku Corporation

  公开号：US20200138964A1

  公开（公告）日：2020-05-07

  Provided is a compound obtained by conjugating a tertiary amine compound or imine compound, which is useful as a drug, with a polymer, in which a structure D + having a quaternary ammonium salt or iminium salt formed from a tertiary amine compound or imine compound D and a polymer residue Poly having a carboxy group are bonded to each other via a structure —C(R 1 )(R 2 )OC(O)ANHC(═O)—.

  提供的是一种化合物，通过将一种三级胺化合物或亚胺化合物与聚合物共轭，用作药物，其中具有由三级胺化合物或亚胺化合物D形成的季铵盐或亚胺盐的结构D + 和具有羧基的聚合物残基Poly通过结构—C(R 1 )(R 2 )OC(O)ANHC(═O)—相互键合。
• [EN] SPECIFIC INHIBITORS OF METHIONYL-TRNA SYNTHETASE<br/>[FR] INHIBITEURS SPÉCIFIQUES DE LA MÉTHIONYL-TARN SYNTHÉTASE
  申请人：UNIV WASHINGTON

  公开号：WO2016029146A1

  公开（公告）日：2016-02-25

  The present disclosure is generally directed to compositions useful in the inhibition of MetRS and methods for treating diseases that are ameliorated by the inhibition of MetRS.

  本公开涉及的是通常用于抑制MetRS的组合物和治疗通过抑制MetRS改善的疾病的方法。
• PRIMARY AMINE COMPOUND OR SECONDARY AMINE COMPOUND-ACIDIC POLYSACCHARIDE CONJUGATE AND PRODUCTION METHOD THEREFOR
  申请人：Seikagaku Corporation

  公开号：US20220040318A1

  公开（公告）日：2022-02-10

  Provided is a novel conjugate of a primary or secondary amine compound with an acidic polysaccharide, which is a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof, where in Formula (I), D, R 1 , R 2 , A, and Poly are as defined in the specification.

  提供的是一种主要或次要胺化合物与酸性多糖结合的新型共轭物，该化合物由式（I）表示或其药用盐，其中在式（I）中，D、R1、R2、A 和 Poly 如规范中定义。
• NITROGENOUS HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF
  申请人：Ochiai Hiroshi

  公开号：US20090233908A1

  公开（公告）日：2009-09-17

  A compound represented by formula (I): (wherein the symbols are the same as defined in the description), a salt thereof, an N-oxide thereof, a solvate thereof or a prodrug thereof, and medicinal use thereof. The compound represented by formula (I) has CXCR4 antagonistic activity. It is hence useful as, e.g., a preventive and/or therapeutic agent for CXCR4-mediated diseases such as inflammatory/immunologic diseases (e.g., rheumatoid arthritis, arthritis, retinopathy, pulmonary fibrosis, and rejection reactions of transplanted organs), allergic diseases, infections diseases (e.g., human immunodeficiency virus infection and acquired immunologic deficiency syndrome), psychoneurotic diseases, cerebral diseases, cardiac/vascular disease, metabolic diseases, cancer diseases (e.g., cancer, cancer metastasis) or as an agent for regeneration therapy.

  化合物的化学式为（I）：（其中符号的定义与说明书中相同），其盐，N-氧化物，溶剂化合物或前药，以及其药用。化合物（I）具有CXCR4拮抗活性。因此，它可用作预防和/或治疗CXCR4介导疾病的药物，例如炎症/免疫疾病（例如类风湿性关节炎，关节炎，视网膜病变，肺纤维化和移植器官的排斥反应），过敏性疾病，感染性疾病（例如人类免疫缺陷病毒感染和获得性免疫缺陷综合症），心理神经疾病，脑部疾病，心血管疾病，代谢性疾病，癌症（例如癌症，癌症转移）或再生治疗剂。
• Azetidine ring compounds and drugs comprising the same
  申请人：Habashita Hiromu

  公开号：US20070135402A1

  公开（公告）日：2007-06-14

  It is intended to provide compounds having EDG-5 antagonism. Because of having EDG-5 antagonism, compounds of the formula (I): wherein each symbol is as defined in the description; salts thereof, N-oxides thereof, solvates thereof or prodrugs thereof are useful as preventive and/or therapeutic agent for EDG-5 mediated diseases, for example, diseases caused by blood vessel contraction (e.g. cerebrovascular spasms disease, cardiovascular spasms diseases, coronary artery spasms disease, hypertension, pulmonary hypertension, renal diseases, myocardial infarction, angina pectoris, arrhythmia, portal hypertension, varicosity and the like), arteriosclerosis, pulmonary fibrosis, hepatic fibrosis, renal fibrosis, respiratory diseases (e.g. bronchial asthma, chronic obstructive pulmonary diseases and the like), nephropathy, diabetes, hyperlipemia and the like.

  本发明旨在提供具有EDG-5拮抗作用的化合物。由于具有EDG-5拮抗作用，式（I）中的化合物：其中每个符号如描述中所定义的，其盐，N-氧化物，溶剂化物或其前药，可用作预防和/或治疗EDG-5介导的疾病的药物，例如血管收缩引起的疾病（例如脑血管痉挛疾病，心血管痉挛疾病，冠状动脉痉挛疾病，高血压，肺动脉高压，肾脏疾病，心肌梗死，心绞痛，心律失常，门脉高压，静脉曲张等），动脉硬化，肺纤维化，肝纤维化，肾脏疾病（例如肾病，糖尿病，高脂血症等）和其他疾病。